RNS & Investor News

2021

Director Appointment

05 January 2021

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skincare, announces that further to the announcement made on 9 December 2020 regarding the intention to appoint Christopher Brinsmead CBE as a Director of the Company, the regulatory due diligence process required for a Board position has been completed, and Chris joined the Board as a Non-Executive Director on 1 January 2021. The text below sets out the required disclosures.

Pursuant to Rule 17 and Schedule 2(g) of the AIM Rules for Companies, the following information is disclosed in respect of Christopher David Brinsmead (aged 61):

Current Appointments

Appointments in the last five years

CDB (Meadowside) Limited

Bamburgh Capital Limited

Peakdata AG

Cambian Group plc (now Cambian Group Limited)

Proveca Limited

Collagen Solutions plc

Scapa Group plc

Consort Medical plc  (now Consort Medical Limited)

 

Datapharm Communications Limited

 

Kinapse Limited

 

UDG Healthcare plc

 

Wesleyan Administration Services Limited

 

Welseyan Assurance Society


Christopher Brinsmead CBE does not currently own any shares or options in the Company.

There is no further information regarding Christopher Brinsmead CBE required to be disclosed under the AIM Rules.

Neil Davidson, Chairman of OptiBiotix commented: "We are pleased to confirm the appointment of Chris to the OptiBiotix Board. Chris's appointment comes at a critical point in the Company's development as it continues to grow sales and expand into international markets with its first generation products, and commercialise its next generation microbiome modulating, SweetBiotix, and drug biotherapeutic products. Chris's pharmaceutical, healthcare, investment, and board experience with a FTSE 350 company complements the current Boards wealth of experience."

 

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

The Directors of the Company accept responsibility for the content of this announcement.

 

For further information, please contact:

OptiBiotix Health plc

www.optibiotix.com

Neil Davidson, Chairman

Stephen O'Hara, Chief Executive

Contact via Walbrook below



Cairn Financial Advisers LLP (NOMAD)

Tel: 020 7213 0880

Liam Murray / Jo Turner / Ludovico Lazzaretti

 


finnCap (Broker)

Tel: 020 7220 0500

Geoff Nash / Kate Bannatyne (Corporate Finance)

 


Walbrook PR Ltd

Mob: 07876 741 001

Anna Dunphy


 

About OptiBiotix - www.optibiotix.com 

OptiBiotix Health plc (AIM: OPTI) is a biotechnology company formed in March 2012 which, brings science and human stuidies to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than seventy international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes. 

 

Caution regarding forward looking statements

Certain statements in this announcement, are, or may be deemed to be, forward looking statements. Forward looking statements are identified by their use of terms and phrases such as ''believe'', ''could'', "should" ''envisage'', ''estimate'', ''intend'', ''may'', ''plan'', ''potentially'', "expect", ''will'' or the negative of those, variations or comparable expressions, including references to assumptions. These forward looking statements are not based on historical facts but rather on the Directors' current expectations and assumptions regarding OptiBiotix's future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward looking statements reflect the Directors' current beliefs and assumptions and are based on information currently available to the Directors.

2020

Director Appointment

05 January 2021

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skincare, announces that further to the announcement made on 9 December 2020 regarding the intention to appoint Christopher Brinsmead CBE as a Director of the Company, the regulatory due diligence process required for a Board position has been completed, and Chris joined the Board as a Non-Executive Director on 1 January 2021. The text below sets out the required disclosures.

Pursuant to Rule 17 and Schedule 2(g) of the AIM Rules for Companies, the following information is disclosed in respect of Christopher David Brinsmead (aged 61):

Current Appointments

Appointments in the last five years

CDB (Meadowside) Limited

Bamburgh Capital Limited

Peakdata AG

Cambian Group plc (now Cambian Group Limited)

Proveca Limited

Collagen Solutions plc

Scapa Group plc

Consort Medical plc  (now Consort Medical Limited)

 

Datapharm Communications Limited

 

Kinapse Limited

 

UDG Healthcare plc

 

Wesleyan Administration Services Limited

 

Welseyan Assurance Society


Christopher Brinsmead CBE does not currently own any shares or options in the Company.

There is no further information regarding Christopher Brinsmead CBE required to be disclosed under the AIM Rules.

Neil Davidson, Chairman of OptiBiotix commented: "We are pleased to confirm the appointment of Chris to the OptiBiotix Board. Chris's appointment comes at a critical point in the Company's development as it continues to grow sales and expand into international markets with its first generation products, and commercialise its next generation microbiome modulating, SweetBiotix, and drug biotherapeutic products. Chris's pharmaceutical, healthcare, investment, and board experience with a FTSE 350 company complements the current Boards wealth of experience."

 

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

The Directors of the Company accept responsibility for the content of this announcement.

 

For further information, please contact:

OptiBiotix Health plc

www.optibiotix.com

Neil Davidson, Chairman

Stephen O'Hara, Chief Executive

Contact via Walbrook below



Cairn Financial Advisers LLP (NOMAD)

Tel: 020 7213 0880

Liam Murray / Jo Turner / Ludovico Lazzaretti

 


finnCap (Broker)

Tel: 020 7220 0500

Geoff Nash / Kate Bannatyne (Corporate Finance)

 


Walbrook PR Ltd

Mob: 07876 741 001

Anna Dunphy


 

About OptiBiotix - www.optibiotix.com 

OptiBiotix Health plc (AIM: OPTI) is a biotechnology company formed in March 2012 which, brings science and human stuidies to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than seventy international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes. 

 

Caution regarding forward looking statements

Certain statements in this announcement, are, or may be deemed to be, forward looking statements. Forward looking statements are identified by their use of terms and phrases such as ''believe'', ''could'', "should" ''envisage'', ''estimate'', ''intend'', ''may'', ''plan'', ''potentially'', "expect", ''will'' or the negative of those, variations or comparable expressions, including references to assumptions. These forward looking statements are not based on historical facts but rather on the Directors' current expectations and assumptions regarding OptiBiotix's future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward looking statements reflect the Directors' current beliefs and assumptions and are based on information currently available to the Directors.

2019

Director Appointment

05 January 2021

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skincare, announces that further to the announcement made on 9 December 2020 regarding the intention to appoint Christopher Brinsmead CBE as a Director of the Company, the regulatory due diligence process required for a Board position has been completed, and Chris joined the Board as a Non-Executive Director on 1 January 2021. The text below sets out the required disclosures.

Pursuant to Rule 17 and Schedule 2(g) of the AIM Rules for Companies, the following information is disclosed in respect of Christopher David Brinsmead (aged 61):

Current Appointments

Appointments in the last five years

CDB (Meadowside) Limited

Bamburgh Capital Limited

Peakdata AG

Cambian Group plc (now Cambian Group Limited)

Proveca Limited

Collagen Solutions plc

Scapa Group plc

Consort Medical plc  (now Consort Medical Limited)

 

Datapharm Communications Limited

 

Kinapse Limited

 

UDG Healthcare plc

 

Wesleyan Administration Services Limited

 

Welseyan Assurance Society


Christopher Brinsmead CBE does not currently own any shares or options in the Company.

There is no further information regarding Christopher Brinsmead CBE required to be disclosed under the AIM Rules.

Neil Davidson, Chairman of OptiBiotix commented: "We are pleased to confirm the appointment of Chris to the OptiBiotix Board. Chris's appointment comes at a critical point in the Company's development as it continues to grow sales and expand into international markets with its first generation products, and commercialise its next generation microbiome modulating, SweetBiotix, and drug biotherapeutic products. Chris's pharmaceutical, healthcare, investment, and board experience with a FTSE 350 company complements the current Boards wealth of experience."

 

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

The Directors of the Company accept responsibility for the content of this announcement.

 

For further information, please contact:

OptiBiotix Health plc

www.optibiotix.com

Neil Davidson, Chairman

Stephen O'Hara, Chief Executive

Contact via Walbrook below



Cairn Financial Advisers LLP (NOMAD)

Tel: 020 7213 0880

Liam Murray / Jo Turner / Ludovico Lazzaretti

 


finnCap (Broker)

Tel: 020 7220 0500

Geoff Nash / Kate Bannatyne (Corporate Finance)

 


Walbrook PR Ltd

Mob: 07876 741 001

Anna Dunphy


 

About OptiBiotix - www.optibiotix.com 

OptiBiotix Health plc (AIM: OPTI) is a biotechnology company formed in March 2012 which, brings science and human stuidies to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than seventy international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes. 

 

Caution regarding forward looking statements

Certain statements in this announcement, are, or may be deemed to be, forward looking statements. Forward looking statements are identified by their use of terms and phrases such as ''believe'', ''could'', "should" ''envisage'', ''estimate'', ''intend'', ''may'', ''plan'', ''potentially'', "expect", ''will'' or the negative of those, variations or comparable expressions, including references to assumptions. These forward looking statements are not based on historical facts but rather on the Directors' current expectations and assumptions regarding OptiBiotix's future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward looking statements reflect the Directors' current beliefs and assumptions and are based on information currently available to the Directors.

2018

Director Appointment

05 January 2021

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skincare, announces that further to the announcement made on 9 December 2020 regarding the intention to appoint Christopher Brinsmead CBE as a Director of the Company, the regulatory due diligence process required for a Board position has been completed, and Chris joined the Board as a Non-Executive Director on 1 January 2021. The text below sets out the required disclosures.

Pursuant to Rule 17 and Schedule 2(g) of the AIM Rules for Companies, the following information is disclosed in respect of Christopher David Brinsmead (aged 61):

Current Appointments

Appointments in the last five years

CDB (Meadowside) Limited

Bamburgh Capital Limited

Peakdata AG

Cambian Group plc (now Cambian Group Limited)

Proveca Limited

Collagen Solutions plc

Scapa Group plc

Consort Medical plc  (now Consort Medical Limited)

 

Datapharm Communications Limited

 

Kinapse Limited

 

UDG Healthcare plc

 

Wesleyan Administration Services Limited

 

Welseyan Assurance Society


Christopher Brinsmead CBE does not currently own any shares or options in the Company.

There is no further information regarding Christopher Brinsmead CBE required to be disclosed under the AIM Rules.

Neil Davidson, Chairman of OptiBiotix commented: "We are pleased to confirm the appointment of Chris to the OptiBiotix Board. Chris's appointment comes at a critical point in the Company's development as it continues to grow sales and expand into international markets with its first generation products, and commercialise its next generation microbiome modulating, SweetBiotix, and drug biotherapeutic products. Chris's pharmaceutical, healthcare, investment, and board experience with a FTSE 350 company complements the current Boards wealth of experience."

 

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

The Directors of the Company accept responsibility for the content of this announcement.

 

For further information, please contact:

OptiBiotix Health plc

www.optibiotix.com

Neil Davidson, Chairman

Stephen O'Hara, Chief Executive

Contact via Walbrook below



Cairn Financial Advisers LLP (NOMAD)

Tel: 020 7213 0880

Liam Murray / Jo Turner / Ludovico Lazzaretti

 


finnCap (Broker)

Tel: 020 7220 0500

Geoff Nash / Kate Bannatyne (Corporate Finance)

 


Walbrook PR Ltd

Mob: 07876 741 001

Anna Dunphy


 

About OptiBiotix - www.optibiotix.com 

OptiBiotix Health plc (AIM: OPTI) is a biotechnology company formed in March 2012 which, brings science and human stuidies to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than seventy international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes. 

 

Caution regarding forward looking statements

Certain statements in this announcement, are, or may be deemed to be, forward looking statements. Forward looking statements are identified by their use of terms and phrases such as ''believe'', ''could'', "should" ''envisage'', ''estimate'', ''intend'', ''may'', ''plan'', ''potentially'', "expect", ''will'' or the negative of those, variations or comparable expressions, including references to assumptions. These forward looking statements are not based on historical facts but rather on the Directors' current expectations and assumptions regarding OptiBiotix's future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward looking statements reflect the Directors' current beliefs and assumptions and are based on information currently available to the Directors.

2017

Director Appointment

05 January 2021

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skincare, announces that further to the announcement made on 9 December 2020 regarding the intention to appoint Christopher Brinsmead CBE as a Director of the Company, the regulatory due diligence process required for a Board position has been completed, and Chris joined the Board as a Non-Executive Director on 1 January 2021. The text below sets out the required disclosures.

Pursuant to Rule 17 and Schedule 2(g) of the AIM Rules for Companies, the following information is disclosed in respect of Christopher David Brinsmead (aged 61):

Current Appointments

Appointments in the last five years

CDB (Meadowside) Limited

Bamburgh Capital Limited

Peakdata AG

Cambian Group plc (now Cambian Group Limited)

Proveca Limited

Collagen Solutions plc

Scapa Group plc

Consort Medical plc  (now Consort Medical Limited)

 

Datapharm Communications Limited

 

Kinapse Limited

 

UDG Healthcare plc

 

Wesleyan Administration Services Limited

 

Welseyan Assurance Society


Christopher Brinsmead CBE does not currently own any shares or options in the Company.

There is no further information regarding Christopher Brinsmead CBE required to be disclosed under the AIM Rules.

Neil Davidson, Chairman of OptiBiotix commented: "We are pleased to confirm the appointment of Chris to the OptiBiotix Board. Chris's appointment comes at a critical point in the Company's development as it continues to grow sales and expand into international markets with its first generation products, and commercialise its next generation microbiome modulating, SweetBiotix, and drug biotherapeutic products. Chris's pharmaceutical, healthcare, investment, and board experience with a FTSE 350 company complements the current Boards wealth of experience."

 

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

The Directors of the Company accept responsibility for the content of this announcement.

 

For further information, please contact:

OptiBiotix Health plc

www.optibiotix.com

Neil Davidson, Chairman

Stephen O'Hara, Chief Executive

Contact via Walbrook below



Cairn Financial Advisers LLP (NOMAD)

Tel: 020 7213 0880

Liam Murray / Jo Turner / Ludovico Lazzaretti

 


finnCap (Broker)

Tel: 020 7220 0500

Geoff Nash / Kate Bannatyne (Corporate Finance)

 


Walbrook PR Ltd

Mob: 07876 741 001

Anna Dunphy


 

About OptiBiotix - www.optibiotix.com 

OptiBiotix Health plc (AIM: OPTI) is a biotechnology company formed in March 2012 which, brings science and human stuidies to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than seventy international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes. 

 

Caution regarding forward looking statements

Certain statements in this announcement, are, or may be deemed to be, forward looking statements. Forward looking statements are identified by their use of terms and phrases such as ''believe'', ''could'', "should" ''envisage'', ''estimate'', ''intend'', ''may'', ''plan'', ''potentially'', "expect", ''will'' or the negative of those, variations or comparable expressions, including references to assumptions. These forward looking statements are not based on historical facts but rather on the Directors' current expectations and assumptions regarding OptiBiotix's future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward looking statements reflect the Directors' current beliefs and assumptions and are based on information currently available to the Directors.

2016

Director Appointment

05 January 2021

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skincare, announces that further to the announcement made on 9 December 2020 regarding the intention to appoint Christopher Brinsmead CBE as a Director of the Company, the regulatory due diligence process required for a Board position has been completed, and Chris joined the Board as a Non-Executive Director on 1 January 2021. The text below sets out the required disclosures.

Pursuant to Rule 17 and Schedule 2(g) of the AIM Rules for Companies, the following information is disclosed in respect of Christopher David Brinsmead (aged 61):

Current Appointments

Appointments in the last five years

CDB (Meadowside) Limited

Bamburgh Capital Limited

Peakdata AG

Cambian Group plc (now Cambian Group Limited)

Proveca Limited

Collagen Solutions plc

Scapa Group plc

Consort Medical plc  (now Consort Medical Limited)

 

Datapharm Communications Limited

 

Kinapse Limited

 

UDG Healthcare plc

 

Wesleyan Administration Services Limited

 

Welseyan Assurance Society


Christopher Brinsmead CBE does not currently own any shares or options in the Company.

There is no further information regarding Christopher Brinsmead CBE required to be disclosed under the AIM Rules.

Neil Davidson, Chairman of OptiBiotix commented: "We are pleased to confirm the appointment of Chris to the OptiBiotix Board. Chris's appointment comes at a critical point in the Company's development as it continues to grow sales and expand into international markets with its first generation products, and commercialise its next generation microbiome modulating, SweetBiotix, and drug biotherapeutic products. Chris's pharmaceutical, healthcare, investment, and board experience with a FTSE 350 company complements the current Boards wealth of experience."

 

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

The Directors of the Company accept responsibility for the content of this announcement.

 

For further information, please contact:

OptiBiotix Health plc

www.optibiotix.com

Neil Davidson, Chairman

Stephen O'Hara, Chief Executive

Contact via Walbrook below



Cairn Financial Advisers LLP (NOMAD)

Tel: 020 7213 0880

Liam Murray / Jo Turner / Ludovico Lazzaretti

 


finnCap (Broker)

Tel: 020 7220 0500

Geoff Nash / Kate Bannatyne (Corporate Finance)

 


Walbrook PR Ltd

Mob: 07876 741 001

Anna Dunphy


 

About OptiBiotix - www.optibiotix.com 

OptiBiotix Health plc (AIM: OPTI) is a biotechnology company formed in March 2012 which, brings science and human stuidies to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than seventy international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes. 

 

Caution regarding forward looking statements

Certain statements in this announcement, are, or may be deemed to be, forward looking statements. Forward looking statements are identified by their use of terms and phrases such as ''believe'', ''could'', "should" ''envisage'', ''estimate'', ''intend'', ''may'', ''plan'', ''potentially'', "expect", ''will'' or the negative of those, variations or comparable expressions, including references to assumptions. These forward looking statements are not based on historical facts but rather on the Directors' current expectations and assumptions regarding OptiBiotix's future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward looking statements reflect the Directors' current beliefs and assumptions and are based on information currently available to the Directors.

2015

Director Appointment

05 January 2021

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skincare, announces that further to the announcement made on 9 December 2020 regarding the intention to appoint Christopher Brinsmead CBE as a Director of the Company, the regulatory due diligence process required for a Board position has been completed, and Chris joined the Board as a Non-Executive Director on 1 January 2021. The text below sets out the required disclosures.

Pursuant to Rule 17 and Schedule 2(g) of the AIM Rules for Companies, the following information is disclosed in respect of Christopher David Brinsmead (aged 61):

Current Appointments

Appointments in the last five years

CDB (Meadowside) Limited

Bamburgh Capital Limited

Peakdata AG

Cambian Group plc (now Cambian Group Limited)

Proveca Limited

Collagen Solutions plc

Scapa Group plc

Consort Medical plc  (now Consort Medical Limited)

 

Datapharm Communications Limited

 

Kinapse Limited

 

UDG Healthcare plc

 

Wesleyan Administration Services Limited

 

Welseyan Assurance Society


Christopher Brinsmead CBE does not currently own any shares or options in the Company.

There is no further information regarding Christopher Brinsmead CBE required to be disclosed under the AIM Rules.

Neil Davidson, Chairman of OptiBiotix commented: "We are pleased to confirm the appointment of Chris to the OptiBiotix Board. Chris's appointment comes at a critical point in the Company's development as it continues to grow sales and expand into international markets with its first generation products, and commercialise its next generation microbiome modulating, SweetBiotix, and drug biotherapeutic products. Chris's pharmaceutical, healthcare, investment, and board experience with a FTSE 350 company complements the current Boards wealth of experience."

 

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

The Directors of the Company accept responsibility for the content of this announcement.

 

For further information, please contact:

OptiBiotix Health plc

www.optibiotix.com

Neil Davidson, Chairman

Stephen O'Hara, Chief Executive

Contact via Walbrook below



Cairn Financial Advisers LLP (NOMAD)

Tel: 020 7213 0880

Liam Murray / Jo Turner / Ludovico Lazzaretti

 


finnCap (Broker)

Tel: 020 7220 0500

Geoff Nash / Kate Bannatyne (Corporate Finance)

 


Walbrook PR Ltd

Mob: 07876 741 001

Anna Dunphy


 

About OptiBiotix - www.optibiotix.com 

OptiBiotix Health plc (AIM: OPTI) is a biotechnology company formed in March 2012 which, brings science and human stuidies to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than seventy international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes. 

 

Caution regarding forward looking statements

Certain statements in this announcement, are, or may be deemed to be, forward looking statements. Forward looking statements are identified by their use of terms and phrases such as ''believe'', ''could'', "should" ''envisage'', ''estimate'', ''intend'', ''may'', ''plan'', ''potentially'', "expect", ''will'' or the negative of those, variations or comparable expressions, including references to assumptions. These forward looking statements are not based on historical facts but rather on the Directors' current expectations and assumptions regarding OptiBiotix's future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward looking statements reflect the Directors' current beliefs and assumptions and are based on information currently available to the Directors.

2014

Director Appointment

05 January 2021

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skincare, announces that further to the announcement made on 9 December 2020 regarding the intention to appoint Christopher Brinsmead CBE as a Director of the Company, the regulatory due diligence process required for a Board position has been completed, and Chris joined the Board as a Non-Executive Director on 1 January 2021. The text below sets out the required disclosures.

Pursuant to Rule 17 and Schedule 2(g) of the AIM Rules for Companies, the following information is disclosed in respect of Christopher David Brinsmead (aged 61):

Current Appointments

Appointments in the last five years

CDB (Meadowside) Limited

Bamburgh Capital Limited

Peakdata AG

Cambian Group plc (now Cambian Group Limited)

Proveca Limited

Collagen Solutions plc

Scapa Group plc

Consort Medical plc  (now Consort Medical Limited)

 

Datapharm Communications Limited

 

Kinapse Limited

 

UDG Healthcare plc

 

Wesleyan Administration Services Limited

 

Welseyan Assurance Society


Christopher Brinsmead CBE does not currently own any shares or options in the Company.

There is no further information regarding Christopher Brinsmead CBE required to be disclosed under the AIM Rules.

Neil Davidson, Chairman of OptiBiotix commented: "We are pleased to confirm the appointment of Chris to the OptiBiotix Board. Chris's appointment comes at a critical point in the Company's development as it continues to grow sales and expand into international markets with its first generation products, and commercialise its next generation microbiome modulating, SweetBiotix, and drug biotherapeutic products. Chris's pharmaceutical, healthcare, investment, and board experience with a FTSE 350 company complements the current Boards wealth of experience."

 

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

The Directors of the Company accept responsibility for the content of this announcement.

 

For further information, please contact:

OptiBiotix Health plc

www.optibiotix.com

Neil Davidson, Chairman

Stephen O'Hara, Chief Executive

Contact via Walbrook below



Cairn Financial Advisers LLP (NOMAD)

Tel: 020 7213 0880

Liam Murray / Jo Turner / Ludovico Lazzaretti

 


finnCap (Broker)

Tel: 020 7220 0500

Geoff Nash / Kate Bannatyne (Corporate Finance)

 


Walbrook PR Ltd

Mob: 07876 741 001

Anna Dunphy


 

About OptiBiotix - www.optibiotix.com 

OptiBiotix Health plc (AIM: OPTI) is a biotechnology company formed in March 2012 which, brings science and human stuidies to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than seventy international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes. 

 

Caution regarding forward looking statements

Certain statements in this announcement, are, or may be deemed to be, forward looking statements. Forward looking statements are identified by their use of terms and phrases such as ''believe'', ''could'', "should" ''envisage'', ''estimate'', ''intend'', ''may'', ''plan'', ''potentially'', "expect", ''will'' or the negative of those, variations or comparable expressions, including references to assumptions. These forward looking statements are not based on historical facts but rather on the Directors' current expectations and assumptions regarding OptiBiotix's future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward looking statements reflect the Directors' current beliefs and assumptions and are based on information currently available to the Directors.

2013

Director Appointment

05 January 2021

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skincare, announces that further to the announcement made on 9 December 2020 regarding the intention to appoint Christopher Brinsmead CBE as a Director of the Company, the regulatory due diligence process required for a Board position has been completed, and Chris joined the Board as a Non-Executive Director on 1 January 2021. The text below sets out the required disclosures.

Pursuant to Rule 17 and Schedule 2(g) of the AIM Rules for Companies, the following information is disclosed in respect of Christopher David Brinsmead (aged 61):

Current Appointments

Appointments in the last five years

CDB (Meadowside) Limited

Bamburgh Capital Limited

Peakdata AG

Cambian Group plc (now Cambian Group Limited)

Proveca Limited

Collagen Solutions plc

Scapa Group plc

Consort Medical plc  (now Consort Medical Limited)

 

Datapharm Communications Limited

 

Kinapse Limited

 

UDG Healthcare plc

 

Wesleyan Administration Services Limited

 

Welseyan Assurance Society


Christopher Brinsmead CBE does not currently own any shares or options in the Company.

There is no further information regarding Christopher Brinsmead CBE required to be disclosed under the AIM Rules.

Neil Davidson, Chairman of OptiBiotix commented: "We are pleased to confirm the appointment of Chris to the OptiBiotix Board. Chris's appointment comes at a critical point in the Company's development as it continues to grow sales and expand into international markets with its first generation products, and commercialise its next generation microbiome modulating, SweetBiotix, and drug biotherapeutic products. Chris's pharmaceutical, healthcare, investment, and board experience with a FTSE 350 company complements the current Boards wealth of experience."

 

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

The Directors of the Company accept responsibility for the content of this announcement.

 

For further information, please contact:

OptiBiotix Health plc

www.optibiotix.com

Neil Davidson, Chairman

Stephen O'Hara, Chief Executive

Contact via Walbrook below



Cairn Financial Advisers LLP (NOMAD)

Tel: 020 7213 0880

Liam Murray / Jo Turner / Ludovico Lazzaretti

 


finnCap (Broker)

Tel: 020 7220 0500

Geoff Nash / Kate Bannatyne (Corporate Finance)

 


Walbrook PR Ltd

Mob: 07876 741 001

Anna Dunphy


 

About OptiBiotix - www.optibiotix.com 

OptiBiotix Health plc (AIM: OPTI) is a biotechnology company formed in March 2012 which, brings science and human stuidies to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than seventy international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes. 

 

Caution regarding forward looking statements

Certain statements in this announcement, are, or may be deemed to be, forward looking statements. Forward looking statements are identified by their use of terms and phrases such as ''believe'', ''could'', "should" ''envisage'', ''estimate'', ''intend'', ''may'', ''plan'', ''potentially'', "expect", ''will'' or the negative of those, variations or comparable expressions, including references to assumptions. These forward looking statements are not based on historical facts but rather on the Directors' current expectations and assumptions regarding OptiBiotix's future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward looking statements reflect the Directors' current beliefs and assumptions and are based on information currently available to the Directors.